Syros Pharmaceuticals – Talk Bio

Actionable Insights Powered by AI

Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)

8 months ago talkbio0Tagged Agonist, azacitidine, Clinical Trials, Futility Analysis, Leukemia, Myelocytic, Acute, RARα, SELECT-AML-1, Syros Pharmaceuticals, tamibarotene, venetoclax

Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis